ipilimumab,nivolumab
bms
['secombit', 'biomarker', 'melanoma']
#esmo2022 presented the update of secombit trial recently published on jco, confirming tendency of better outcome with immuno first vs target therapy and interesting preliminary biomarkers data #melanoma 
Scientific Director Istituto Nazionale Tumori - IRCCS G. Pascale